StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 17/3038% above fair value
$698.47+8.23 (+1.19%)

Close on Nov 18, 2026Market cap $55.03BP/E 49.1Yield –

IDEXX Laboratories operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

IDEXX Laboratories's operating income for the twelve months ending Jun 30, 2026 was $1.46B, up 16.2% year over year. For fiscal 2025 it was $1.36B, up 20.5% from the year before. Over ten years it grew 16.3% a year on average. The highest annual figure on record is $1.36B in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.36B+20.5%
FY2024Dec 31, 2024$1.13B+2.8%
FY2023Dec 31, 2023$1.10B+22.1%
FY2022Dec 31, 2022$898.77M-3.6%
FY2021Dec 31, 2021$932.03M+34.2%
FY2020Dec 31, 2020$694.52M+25.6%
FY2019Dec 31, 2019$552.85M+12.5%
FY2018Dec 31, 2018$491.34M+19.0%
FY2017Dec 31, 2017$413.03M+17.9%
FY2016Dec 31, 2016$350.24M+16.8%
FY2015Dec 31, 2015$299.91M+15.2%
FY2014Dec 31, 2014$260.26M-2.4%
FY2013Dec 31, 2013$266.76M+1.6%
FY2012Dec 31, 2012$262.56M+11.1%
FY2011Dec 31, 2011$236.23M+15.9%
FY2010Dec 31, 2010$203.88M+15.9%
FY2009Dec 31, 2009$175.97M+2.0%
FY2008Dec 31, 2008$172.46M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$425.57M+14.1%
Q1 FY2026Mar 31, 2026$362.59M+14.5%
Q4 FY2025Dec 31, 2025$315.61M+20.6%
Q3 FY2025Sep 30, 2025$354.85M+16.8%
Q2 FY2025Jun 30, 2025$373.05M+41.4%
Q1 FY2025Mar 31, 2025$316.53M+5.9%
Q4 FY2024Dec 31, 2024$261.69M+6.7%
Q3 FY2024Sep 30, 2024$303.89M+10.4%
Q2 FY2024Jun 30, 2024$263.80M-10.9%
Q1 FY2024Mar 31, 2024$298.96M+6.6%
Q4 FY2023Dec 31, 2023$245.30M+8.3%
Q3 FY2023Sep 30, 2023$275.28M+12.4%
Q2 FY2023Jun 30, 2023$296.14M+65.4%
Q1 FY2023Mar 31, 2023$280.40M+12.9%
Q4 FY2022Dec 31, 2022$226.53M+13.7%
Q3 FY2022Sep 30, 2022$244.83M+8.3%
Q2 FY2022Jun 30, 2022$179.07M-30.9%
Q1 FY2022Mar 31, 2022$248.34M+0.3%
Q4 FY2021Dec 31, 2021$199.19M+7.6%
Q3 FY2021Sep 30, 2021$225.96M+31.5%
Q2 FY2021Jun 30, 2021$259.25M+34.2%
Q1 FY2021Mar 31, 2021$247.62M+71.6%
Q4 FY2020Dec 31, 2020$185.10M+60.1%
Q3 FY2020Sep 30, 2020$171.86M+22.9%
Q2 FY2020Jun 30, 2020$193.25M+17.6%
Q1 FY2020Mar 31, 2020$144.33M+8.4%
Q4 FY2019Dec 31, 2019$115.63M+0.2%
Q3 FY2019Sep 30, 2019$139.80M+19.1%
Q2 FY2019Jun 30, 2019$164.28M+12.8%
Q1 FY2019Mar 31, 2019$133.14M+17.8%
Q4 FY2018Dec 31, 2018$115.35M+17.9%
Q3 FY2018Sep 30, 2018$117.35M+16.9%
Q2 FY2018Jun 30, 2018$145.59M+18.8%
Q1 FY2018Mar 31, 2018$113.04M+22.6%
Q4 FY2017Dec 31, 2017$97.81M+16.7%
Q3 FY2017Sep 30, 2017$100.41M+13.5%
Q2 FY2017Jun 30, 2017$122.56M–
Q1 FY2017Mar 31, 2017$92.24M–
Q4 FY2016Dec 31, 2016$83.83M–
Q3 FY2016Sep 30, 2016$88.46M–

More IDEXX Laboratories figures

See a number that looks wrong?